HPV-related oropharyngeal carcinoma de-escalation protocols
Mené sur 45 patients atteints d'un carcinome épidermoïde de l'oropharynx lié à une infection par le papillomavirus humain de type 16 (âge médian : 60 ans), cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'une chimiothérapie d'induction à base de paclitaxel et de carboplatine suivie d'une radiothérapie à doses réduites de 15 à 20 %
Human papillomavirus (HPV) is now recognised as the principal cause of the increasing incidence of oropharyngeal squamous-cell carcinoma in developed countries. HPV-related oropharyngeal squamous-cell carcinomas have epidemiological, molecular, and clinical characteristics different from those caused by classic risk factors (eg, tobacco and alcohol consumption). Most importantly, however, positive HPV status is an independent predictor of improved overall survival and treatment responsiveness.1 Additionally, patients with HPV-related oropharyngeal squamous-cell carcinoma tend to be younger than patients with non-HPV-related disease2 and to have high treatment-related morbidity that can substantially impair quality of life.
The Lancet Oncology , commentaire, 2016